C12N 2760/18163
By chemical treatment
Official title: by chemical treatment
C12N2760/18163 (By chemical treatment) appears on 6 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 6
- Published applications
- 9
- Assignees
- 6
- Inventors
- 18
- Latest grant
- 12 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 1 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof12 Aug 2025US 12,385,068 B2Boehringer Ingelheim Animal Health USA Inc.
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof23 Aug 2022US 11,421,249 B2Boehringer Ingelheim Animal Health USA Inc.
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof3 Nov 2020US 10,822,620 B2Boehringer Ingelheim Animal Health USA Inc.
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof18 Jun 2019US 10,323,257 B2Boehringer Ingelheim Animal Health USA Inc.
- Newcastle disease virus and the use thereof as a vaccine21 Jun 2016US 9,370,563 B2Investigación Aplicada S.A. de C.V.
- Recombinant hvt vectors expressing multiple antigens of avian pathogens and uses thereof30 Oct 2025US 2025/0333766 A1Boehringer Ingelheim Animal Health USA Inc.
- Recombinant hvt vectors expressing multiple antigens of avian pathogens and uses thereof8 Jun 2023US 2023/0175017 A1Boehringer Ingelheim Animal Health USA Inc.
- Recombinant hvt vectors expressing multiple antigens of avian pathogens and uses thereof14 Jan 2021US 2021/0010033 A1Boehringer Ingelheim Animal Health USA Inc.
- Recombinant hvt vectors expressing multiple antigens of avian pathogens and uses thereof15 Aug 2019US 2019/0249196 A1Boehringer Ingelheim Animal Health USA Inc.
- Recombinant hvt vectors expressing multiple antigens of avian pathogens and uses thereof14 Jun 2018US 2018/0163230 A1Merial Limited
Most cited
By later US patents
- Embryonal vaccine against Newcastle disease10US 5,427,791 ARegents of the University of Minnesota · 1995
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof6US 10,323,257 B2Boehringer Ingelheim Animal Health USA Inc. · 2019
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof3US 10,822,620 B2Boehringer Ingelheim Animal Health USA Inc. · 2020
- Newcastle disease virus and the use thereof as a vaccine2US 9,370,563 B2Investigación Aplicada S.A. de C.V. · 2016